Video

Orally Administered Botanical Therapies Targeting ASD With DeFloria's Jared And Joel Stanley

Source: Drug Delivery Leader

In this episode of Sit and Deliver, host Tom von Gunden talks with Jared Stanley, CEO, and Joel Stanley, board chairman, from DeFloria, a botanical therapeutics development company. Tom talks with the Stanley brothers about cannabinoid-based therapies targeting Autism Spectrum Disorder (ASD). The discussion covers aspects of drug development and delivery including molecule characterization, formulation, and dosing for oral administration, as well as key considerations for commercial-scale production and distribution of regulated botanicals.

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Delivery Leader? Subscribe today.

Subscribe to Drug Delivery Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Drug Delivery Leader